Imperagen Secures £5M Seed Funding
Analysis based on 9 articles · First reported May 21, 2026 · Last updated May 21, 2026
The successful seed funding round for Imperagen is expected to boost investor confidence in the biotechnology sector, particularly in AI-driven enzyme engineering. This investment will enable Imperagen to accelerate its R&D and expand its market reach, potentially leading to advancements in pharmaceuticals, personal care, and sustainable chemical production, which could positively impact related industries and their stock performance.
Imperagen, a techbio company based in Manchester and a spin-out from the University of Manchester, has successfully closed a £5 million seed funding round, bringing its total funding to £8.5 million. The round was led by PXN Ventures, with continued participation from existing investors IQ Capital and Northern Gritstone. This capital injection will be used to accelerate Imperagen's research and development, expand its wet lab capabilities, and strengthen its go-to-market strategy over the next 18 months. Concurrently, Guy Levy-Yurista, an experienced technology and life sciences executive, has joined Imperagen as CEO to lead its growth. Imperagen's proprietary platform combines quantum physics simulations, AI modeling, and automated robotics in a closed-loop system to engineer enzymes more efficiently and predictably. The company has already demonstrated significant success, including improving enzyme productivity by over 670x for a Fortune 500 personal care company. The investment highlights the growing strength of the North West's life sciences ecosystem in the United Kingdom.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard